Successes in therapeutic targeting of PD-1 and CTLA-4 pathways in T lymphocytes are viewed as clinical evidence supporting the notion of cancer surveillance by cells of the adaptive immune system akin to that of pathogens. The gene discussed is CTLA4; the disease is cancer.